SCHEMBL6322992

SCHEMBL6322992

COC(=O)CCc1nc(-c2ccc(CO[Si](C(C)C)(C(C)C)C(C)C)cc2)no1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.51
ATM Q13315 1/20 0.51
ALDH1A1 P00352 4/20 0.47
GAA P10253 2/20 0.47
TP53 P04637 3/20 0.47
MAPT P10636 3/20 0.47
NPC1 O15118 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
MITF O75030 1/20 0.47
NCOA3 Q9Y6Q9 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 2/20 0.46
TSHR P16473 2/20 0.46
RAB9A P51151 2/20 0.46
POLB P06746 1/20 0.45
HDAC1 Q13547 1/20 0.45
KLF5 Q13887 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
FFAR1 O14842 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325624 0.88 TSHR (0.49) LMNAALDH1A1GAAMAPTCYP1A2
SCHEMBL6326028 0.86 LMNA (0.57) LMNAATMALDH1A1TP53MAPT
SCHEMBL6327182 0.83 LMNA (0.52) LMNAATMALDH1A1GAATP53
SCHEMBL6323837 0.83 TP53 (0.55) LMNAATMALDH1A1TP53MAPT
SCHEMBL6325140 0.83 LMNA (0.58) LMNAATMALDH1A1TP53MAPT
SCHEMBL6333033 0.82 LMNA (0.61) LMNAATMALDH1A1TP53MAPT
SCHEMBL6334437 0.80 ACACB (0.62) LMNAATMALDH1A1GAATP53
SCHEMBL4564362 0.79 HPGD (0.68) LMNAATMALDH1A1GAATP53
SCHEMBL6326185 0.76 TP53 (0.78) LMNAATMALDH1A1TP53MAPT
SCHEMBL6332720 0.76 LMNA (0.73) LMNAATMALDH1A1TP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 EP disclosed
US-6924284-B2 PARP inhibitors ICOS CORPORATION (US) 2005-08-02 US disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 LMNA 448/4885ATM 414/4885ALDH1A1 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.